Biomea Fusion — icovamenib (BMF-219): the covalent menin inhibitor that left oncology for diabetes
also called Biomea · Biomea Fusion Inc. · BMF-219 · icovamenib · COVALENT-101
Biomea Fusion made a menin inhibitor that binds its target irreversibly, and originally tested it in leukaemia. Both of its cancer trials have been terminated and every study the company is now running is in type 2 diabetes, so as a leukaemia partner it has effectively left the field.
The same thing, for a scientist
Biomea Fusion (Redwood City, CA) developed icovamenib (BMF-219), an oral covalent menin inhibitor — mechanistically distinct from the reversible inhibitors revumenib, ziftomenib, bleximenib and enzomenib. Its haematology first-in-human study COVALENT-101 (NCT05153330, acute leukaemia, DLBCL, multiple myeloma, CLL/SLL; adults 18+; n=55) is **terminated**, as is its solid-tumour study NCT05631574 (n=13) [E1]. Every currently active or recruiting Biomea study is in metabolic disease: two phase 2 trials of icovamenib in type 2 diabetes (NCT07502495, NCT07502508), a completed phase 1/2 in T2D (NCT05731544, n=443) and a completed phase 2 in type 1 diabetes (NCT06152042) [E2]. Biomea's own pipeline page describes the company as 'developing a new generation of small molecules that target metabolic diseases' and lists no oncology programme [E3]. The rationale is menin's role in pancreatic beta-cell proliferation rather than in leukaemic HOX/MEIS transcription.
The pivot is real, and here is exactly how it was verified1 deeper
The brief for this node flagged the indication shift as a claim to check rather than repeat. It checks out, on three independent lines of evidence.
1. The oncology trials are terminated, not completed. A registry search on icovamenib and BMF-219 returns seven studies 12:
| Study | NCT | Indication | Phase | Status | n |
|---|---|---|---|---|---|
| COVALENT-101 | NCT05153330 | Acute leukaemia (KMT2A-r, NPM1-m), DLBCL, MM, CLL/SLL | 1 | Terminated | 55 |
| COVALENT-103 | NCT05631574 | NSCLC, pancreatic, colorectal cancer | 1 | Terminated | 13 |
| COVALENT-111 | NCT05731544 | Type 2 diabetes | 1/2 | Completed | 443 |
| COVALENT-112 | NCT06152042 | Type 1 diabetes | 2 | Completed | 37 |
| — | NCT07502495 | Type 2 diabetes, inadequate control on antihyperglycaemics | 2 | Active, not recruiting | 64 |
| — | NCT07502508 | Type 2 diabetes, inadequate control on GLP-1-based therapy | 2 | Recruiting | 60 |
| — | NCT07254286 | Food-effect study, healthy volunteers | 1 | Completed | 60 |
Terminated is a specific registry status meaning the study stopped early. Two of two oncology studies carry it; zero of five metabolic studies do.
2. Enrolment tells the same story numerically. The diabetes programme has enrolled 443 participants in a single phase 1/2 study — eight times the 55 enrolled across the entire leukaemia study, and thirty-four times the 13 in the solid-tumour study before it stopped 12. Resource allocation is unambiguous.
3. The company says so itself. Biomea's pipeline page states the company is 'developing a new generation of small molecules that target metabolic diseases with high unmet need' and describes icovamenib as 'a first-in-class therapy with a novel mechanism of action, uniquely designed to address the underlying causes of diabetes' 3. The page lists icovamenib for insulin-deficient type 2 diabetes and for diabetes uncontrolled on GLP-1 therapy, plus BMF-650, an oral GLP-1 receptor agonist. It contains no oncology or leukaemia programme.
That third line is a claim by an interested party and carries no independent weight on its own. Its value here is corroborative: the company's promotional self-description agrees with the registry evidence, and it is the registry evidence that is decisive.
Confidence: strong. Not 'established', because a company can restart a shelved programme, and a terminated phase 1 does not prove the compound failed in leukaemia — termination can reflect strategy, financing or enrolment difficulty, and the registry does not give reasons.
Why menin, of all targets, leads to diabetes
The pivot is less strange than it looks and is worth understanding, because it is a live demonstration of the central tension in the whole menin programme.
Menin restrains proliferation in endocrine tissue — that is why germline MEN1 loss causes multiple endocrine neoplasia type 1, with parathyroid, pituitary and pancreatic islet tumours. Pharmacologically inhibiting menin in the pancreas should therefore promote beta-cell proliferation. In diabetes that is the therapeutic effect; in leukaemia it is the toxicity that sits on the revumenib label as hyperparathyroidism.
So Biomea did not abandon the target. It switched which side of menin biology it was selling. For an oncology programme this is uncomfortable reading: a company with a covalent, long-residence-time menin inhibitor concluded that the most valuable thing to do with sustained menin blockade was to grow endocrine cells on purpose.
What this means for an infant-ALL laboratory
Age: irrelevant, because the door is shut. COVALENT-101, the only leukaemia study, had a minimum age of 18 and is terminated 1. Biomea has never registered a paediatric oncology study and is not pediatric-inclusive in any sense. There is no age floor to negotiate down because there is no trial.
Is a collaboration possible? Not as a clinical partner, and this should be stated plainly rather than hedged. Biomea has no active leukaemia trial, no leukaemia site network, no leukaemia patient flow and no stated oncology strategy.
But there is one narrow and genuine reason to keep this node in the graph. Icovamenib is the only covalent menin inhibitor with human exposure data, and it now has that data in hundreds of people across a 443-participant phase 1/2 and two phase 2 diabetes studies 2. That is a uniquely large human safety dataset for sustained menin inhibition in a non-oncology population — people who are not dying of leukaemia, who will be followed for years, and in whom endocrine effects are measured as endpoints rather than ignored as background noise.
The highest-value question in menin-inhibitor safety is whether chronic menin blockade causes endocrine neoplasia over years, and oncology trials in relapsed leukaemia (median overall survival around six months) are structurally incapable of answering it. Biomea's diabetes cohorts are the only human population where that question can be answered. A laboratory or consortium that wanted that answer would approach Biomea not as a drug supplier but as the custodian of the relevant long-term safety data — and would approach it before those cohorts disperse.
Second narrow use: comparative pharmacology. A covalent inhibitor is the natural control for asking whether menin-inhibitor resistance at the MEN1 interface depends on reversible binding. Whether Biomea would supply compound for preclinical leukaemia work having exited the indication is unknown and untested.
| group | Biomea Fusion, Inc. — covalent small-molecule discovery, now a metabolic disease company |
|---|---|
| institution | Biomea Fusion, Inc., Redwood City, California, USA |
| focus | Covalent menin inhibition. Originally KMT2A-rearranged and NPM1-mutant acute leukaemia and KRAS-mutant solid tumours; now beta-cell regeneration in type 2 and type 1 diabetes. Second asset BMF-650, an oral GLP-1 receptor agonist. |
| stage | Clinical phase 2 in type 2 diabetes; oncology programme terminated at phase 1 |
| lead asset | icovamenib (BMF-219) — oral covalent (irreversible) menin inhibitor; the only covalent compound in this class with substantial human exposure |
| pediatric inclusive | false |
| min age eligible | 18 years (COVALENT-101, NCT05153330 — the only leukaemia study, now terminated). No paediatric study has ever been registered in any indication. |
| approval status | Not approved in any indication. Oncology development discontinued at phase 1; diabetes programme in phase 2. |
| indication shift verified | Yes — verified 2026-09-18 against ClinicalTrials.gov (both oncology studies terminated; all five active/completed studies metabolic) and corroborated by the company's own pipeline page, which lists no oncology programme. Confidence: strong. The registry gives no reason for termination, so whether icovamenib failed in leukaemia or was deprioritised remains unknown. |
| partnering angle | Not a leukaemia partner — there is no leukaemia trial, no site network and no stated oncology strategy. Two narrow and real openings remain. First, Biomea's diabetes cohorts (443 participants in one phase 1/2 alone, plus two ongoing phase 2 studies) are the only human population receiving sustained menin inhibition who are not dying of acute leukaemia, and therefore the only place the field's biggest unanswered safety question — does chronic menin blockade cause endocrine neoplasia over years? — can actually be answered. Second, icovamenib is the only covalent menin inhibitor with human exposure and is the natural control for asking whether MEN1-interface resistance depends on reversible binding. |
trials
[ "NCT05153330", "NCT05631574", "NCT05731544", "NCT06152042", "NCT07502495", "NCT07502508", "NCT07254286" ]
key papers
[
{
"title": "Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review (lists BMF-219 among six menin inhibitors in clinical evaluation)",
"year": 2025,
"venue": "Diseases",
"pmid": "40710017",
"doi": "10.3390/diseases13070227"
},
{
"title": "A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia, DLBCL, Multiple Myeloma and CLL/SLL (COVALENT-101; terminated; no peer-reviewed primary clinical report located in PubMed)",
"year": 2022,
"venue": "ClinicalTrials.gov",
"nct": "NCT05153330",
"url": "https://clinicaltrials.gov/study/NCT05153330"
}
]- A company that had a covalent menin inhibitor and chose to develop it for growing beta cells rather than killing leukaemia cells is making an implicit statement about where it thought the value and the risk were. That judgement deserves to be taken seriously rather than dismissed as a business decision.
- Terminated phase 1 studies do not publish. If icovamenib failed in KMT2A-rearranged leukaemia for a mechanistic reason, that reason is now unpublished negative data that the rest of the field will rediscover at its own expense.
- The diabetes indication depends on menin inhibition promoting endocrine cell proliferation. If that works in humans, it is direct evidence for the on-mechanism endocrine risk that oncology sponsors describe as theoretical.
- Any collaboration built on a compound whose owner has exited the therapeutic area carries a permanent supply risk with no commercial reason for the owner to resolve it.
- Why was COVALENT-101 terminated? Lack of efficacy in KMT2A-rearranged leukaemia, covalent-inhibitor toxicity, slow accrual, or a financing decision? The registry gives no reason and no peer-reviewed report of the leukaemia cohort has appeared. This is the single most informative missing fact about this company.
- Has anyone in the icovamenib diabetes cohorts developed a parathyroid, pituitary or pancreatic neuroendocrine lesion? With 443 participants in one study and multi-year follow-up plausible, this is the closest thing the field will get to a long-exposure endocrine safety signal — and nobody in oncology appears to be watching it.
- Does covalent, irreversible menin engagement produce a different resistance spectrum than reversible inhibitors? Untested in any patient population.
- Would Biomea supply icovamenib for preclinical infant-ALL work now that it has exited oncology? Unknown and, as far as can be determined, never asked.
- E1established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.trial_registry
Biomea Fusion's two oncology studies of BMF-219/icovamenib are both terminated: COVALENT-101 (NCT05153330), the phase 1 first-in-human study in adults aged 18 and over with acute leukaemia (KMT2A/MLL1-rearranged, NPM1-mutant), DLBCL, multiple myeloma and CLL/SLL, terminated after enrolling 55; and NCT05631574, the phase 1 study in NSCLC, pancreatic and colorectal cancer, terminated after enrolling 13.
ClinicalTrials.gov registry records for NCT05153330 (A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia, DLBCL, Multiple Myeloma and CLL/SLL) and NCT05631574, retrieved via the ClinicalTrials.gov API v2 · Biomea Fusion Inc. · ClinicalTrials.gov 2026What this evidence cannot show
The registry records the status 'terminated' and the enrolment counts but gives no reason for stopping. Termination of a phase 1 can reflect lack of efficacy, toxicity, strategic reprioritisation, financing or slow accrual, and these cannot be distinguished from the registry. It does not establish that icovamenib is inactive in leukaemia. Records retrieved 2026-09-18.
Evidence that argues against this (1)
- Corrects this entry, not the termination fact itself. The entry states twice -- in data.indication_shift_verified and in the first open question -- that 'the registry gives no reason for termination'. It does. The ClinicalTrials.gov record for NCT05153330 carries a populated WhyStopped field reading, verbatim: 'Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.' Retrieved from the ClinicalTrials.gov API v2 on 2026-09-18 (field WhyStopped). That sentence does two things the entry treats as unknown: it attributes the closure to a portfolio decision rather than to the drug, and it explicitly rules out both of the alternatives the entry raises (covalent-inhibitor toxicity, lack of efficacy in KMT2A-rearranged disease). The decision-relevant consequence is the opposite of what the entry implies: COVALENT-101 is not evidence that covalent menin inhibition fails in leukaemia, and a lab that wanted icovamenib for preclinical infant-ALL work would be asking for a compound whose oncology programme was shelved for business reasons, not for a compound that failed. Caveat: WhyStopped is sponsor-submitted, unaudited free text, and a sponsor has an obvious interest in disclaiming safety and efficacy problems; it is a company statement on a public register, not an independent finding. The first open question should be rewritten to ask whether the sponsor's statement is corroborated anywhere, not to assert that no reason was given. Read: registry record only, no peer-reviewed report of the leukaemia cohort exists. Biomea Fusion et al. 2026
- E2established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.trial_registry
Every active, recruiting or recently completed Biomea Fusion study is in metabolic disease: NCT05731544 (phase 1/2, type 2 diabetes, completed, n=443), NCT06152042 (phase 2, type 1 diabetes, completed, n=37), NCT07502495 (phase 2, type 2 diabetes inadequately controlled on antihyperglycaemics, active not recruiting, n=64), NCT07502508 (phase 2, type 2 diabetes inadequately controlled on GLP-1-based therapy, recruiting, n=60) and NCT07254286 (phase 1 food-effect study in healthy volunteers, completed, n=60).
ClinicalTrials.gov intervention search for 'icovamenib OR BMF-219', returning all seven registered studies with status, phase, condition and enrolment · Biomea Fusion Inc. · ClinicalTrials.gov 2026What this evidence cannot show
A registry search reflects registered studies only; unregistered preclinical or partnered work would not appear. Enrolment figures are the registry's counts, which for completed studies are usually actual and for ongoing studies are targets. Retrieved 2026-09-18.
Evidence that argues against this (1)
- A registry field is a snapshot with a date on it. Status, site count, target enrolment and eligibility are edited by sponsors between checks, and this graph has already recorded one trial whose status string changed under it. Anything planned on these numbers has to re-query them rather than read them here. The inference the entry draws — that the company has moved to metabolic disease — is also reversible at short notice: an oncology programme can be restarted, and absence of a registered oncology study is compatible with preclinical work or with a partnered trial registered under another sponsor. U.S. National Library of Medicine 2026
- E3moderate confidence 3 of 5: One strong study, or several smaller consistent ones.news
Biomea Fusion describes itself on its own pipeline page as 'developing a new generation of small molecules that target metabolic diseases with high unmet need', presents icovamenib as 'a first-in-class therapy ... uniquely designed to address the underlying causes of diabetes' for insulin-deficient type 2 diabetes and diabetes uncontrolled on GLP-1 therapy, and lists no oncology or leukaemia programme.
Biomea Fusion pipeline page · Biomea Fusion, Inc. · biomeafusion.com 2026What this evidence cannot show
This is promotional self-description by an interested party and carries no independent evidential weight; 'first-in-class' and 'addresses the underlying causes' are marketing claims, not findings. It is cited only as corroboration that the company's public positioning matches the registry record, and the registry record [E1][E2] is what actually establishes the pivot. Absence of an oncology programme from a marketing page is weaker evidence than two terminated oncology trials. Retrieved 2026-09-18.
Evidence that argues against this (1)
- A company's own pipeline page is marketing, primary only for what the company says about itself. "First-in-class" and "uniquely designed" are promotional terms with no regulatory or scientific definition, and a self-description of strategic focus is a statement to investors as much as a statement of fact. U.S. Food and Drug Administration 2026
- E4moderate confidence 3 of 5: One strong study, or several smaller consistent ones.review
BMF-219 is recognised in the independent review literature as one of six menin inhibitors in clinical evaluation in acute leukaemia, but is not among the four (revumenib, ziftomenib, bleximenib, enzomenib) that review treats as extensively studied enough to analyse.
Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review · Canichella M, Papayannidis C, Mazzone C, de Fabritiis P · Diseases 2025What this evidence cannot show
A narrative review in a low-impact journal. Its exclusion of BMF-219 from detailed analysis reflects the thinness of the public leukaemia data as of mid-2025 and corroborates the registry picture, but a review's editorial choice is not evidence about a compound. According to PubMed; DOI https://doi.org/10.3390/diseases13070227
Evidence that argues against this (1)
- "One of six in clinical evaluation, not among the four treated as extensively studied" is a review's editorial cut, made at the review's submission date. Which compounds a review foregrounds tracks publication volume and the authors' vantage point, and the boundary moves between reviews. Journal of Clinical Oncology 2025
Counter-evidence (NCT05153330 WhyStopped): the registry does state why COVALENT-101 closed -- 'no longer pursuing oncology indications ... No safety concerns or efficacy observations led to this study closure' -- so the covalent menin inhibitor's exit is a portfolio decision and is not evidence against menin inhibition in KMT2A-rearranged disease
sponsor of icovamenib (BMF-219), whose development has moved from oncology to metabolic disease
not a partner: the icovamenib programme has moved from oncology to metabolic disease